市場調查報告書
商品編碼
1017255

臨床營養市場的成長機會、成長預測 (2021-2028年):各給藥途徑、用途、終端用戶、地區

Clinical Nutrition Market by Route of Administration, Application, and End User : Global Opportunity Analysis and Industry Forecast, 2021-2028

出版日期: | 出版商: Allied Market Research | 英文 205 Pages | 商品交期: 2-3個工作天內

價格
  • 全貌
  • 簡介
  • 目錄
簡介

全球臨床營養的市場規模在預測期間內預計以5.3%的年複合成長率發展,從2018年的3135億7800萬美元,成長到2026年5525億300萬美元的規模。

隨著發炎性腸道疾病和糖尿病等的慢性疾病和文明病增加,臨床營養的需求增加。老年人口增加和戰後嬰兒潮世代的人口增加,政府對醫療領域的R&D投資增加等要素也推動市場成長。同時,認知度低和嚴格的法規妨礙市場進一步成長。

本報告提供全球臨床營養的市場調查,市場定義和概要,新型冠狀病毒感染疾病 (COVID-19) 以及其他的市場影響因素分析,市場規模的變化、預測,給藥途徑、用途、終端用戶、地區/主要國家等各種區分的明細,競爭環境,主要企業簡介等彙整資訊。

第1章 簡介

第2章 摘要整理

第3章 市場概要

  • 市場定義、範圍
  • 市場動態
    • 促進因素
    • 阻礙因素
    • 市場機會
  • COVID-19的影響

第4章 市場分析、預測:各給藥途徑

  • 口服
  • 經腸
  • 非口服
    • 主要趨勢、成長機會
    • 市場規模、預測
    • 市場分析:各國

第5章 市場分析、預測:各用途

  • 癌症
  • 神經疾病
  • 腸胃障礙
  • 代謝障礙
  • 其他
    • 市場規模、預測
    • 市場分析:各國

第6章 市場分析、預測:各終端用戶

  • 兒童
  • 成人
  • 老年
    • 市場規模、預測
    • 市場分析:各國

第7章 市場分析、預測:各地區、主要國家

  • 北美
  • 歐洲
  • 亞太地區
  • 南美、中東、非洲
    • 主要趨勢、成長機會
    • 市場規模、預測:各國
    • 市場規模、預測:各給藥途徑
    • 市場規模、預測:各用途
    • 市場規模、預測:各終端用戶

第8章 企業簡介

  • ABBOTT LABORATORIES
  • B. BRAUN MELSUNGEN AG
  • BAXTER INTERNATIONAL INC.
  • DANONE NUTRICIA
  • FRESENIUS SE & CO. KGAA
  • HERO NUTRITIONALS INC.
  • LONZA LTD.
  • NESTLE S.A.
  • PERRIGO COMPANY PLC
  • PFIZER INC.
目錄
Product Code: A00717

The global clinical nutrition market size was valued at $313.578 billion in 2018, and is projected to reach $552.503 billion by 2026, growing at a CAGR of 5.3% from 2019-2026. Clinical nutrition product is a type of pharmaceutical product that helps to keep a patient healthy. It helps to improve the metabolic system by providing adequate supplements such as minerals, vitamins, and others. Clinical nutrition diagnose and treat diseases that affect the intake, intestinal absorption, and metabolism of constituents of the diet, and help promote health through prevention of diet-related diseases. It works in both acute and ambulatory care settings, which includes cardiac rehabilitation, renal dialysis, diabetes, pediatrics, nutrition support, cancer, trauma, wellness centers, and community-based intervention programs.

There is an increase in the demand for clinical nutrition owing to increase in chronic and lifestyle related disease such as inflammatory bowel disease and diabetes mellitus. Furthermore, rise in geriatric population and rise in population of a baby boomers further contributes to the market growth. Moreover, rise in R&D investments made by government in the healthcare sector drives the growth of the clinical nutrition market. However, lack of awareness and stringent regulations restrain the market growth. On the contrary, rise in advancements in clinical nutrition. Further, rise in demand of the clinical nutrition in the emerging countries such as Asia-Pacific and LAMEA and increase in home care usage of the nutritional products are expected to offer lucrative opportunities for the global clinical nutrition market players.

The global clinical nutrition market is segmented on the basis of route of administration, application, end user, and region. By route of administration, the market is classified into oral, enteral, and parenteral. On the basis of application, the market is categorized into cancer, neurological diseases, gastrointestinal disorders, metabolic disorders, and others. By end user, the market is segmented into pediatric, adults, and geriatric. Region wise, the market is analyzed across North America, Europe, Asia-Pacific, and LAMEA.

KEY BENEFITS FOR STAKEHOLDERS

  • This report provides a detailed quantitative analysis of the current market trends and future estimations from 2019-2026, which assists to identify the prevailing market opportunities.
  • An in-depth analysis of various regions is anticipated to provide a detailed understanding of the current trends to enable stakeholders to formulate region-specific plans.
  • A comprehensive analysis of the factors that drive and restrain the growth of the global clinical nutrition market is provided.
  • An extensive analysis of various regions provides insights that allow companies to strategically plan their business moves.

KEY MARKET SEGMENTS

By Route Of Administration

  • Oral
  • Enteral
  • Parenteral

By Application

  • Cancer
  • Neurological Diseases
  • Gastrointestinal Disorders
  • Metabolic Disorders
  • Others

By End User

  • Pediatric
  • Adults
  • Geriatric

By Region

  • North America
  • U.S.
  • Canada
  • Mexico
  • Europe
  • Germany
  • France
  • Spain
  • Italy
  • UK
  • Rest of Europe
  • Asia-Pacific
  • Japan
  • India
  • China
  • Australia
  • Rest of Asia-Pacific
  • LAMEA
  • Brazil
  • Saudi Arabia
  • South Africa
  • Rest of LAMEA

KEY MARKET PLAYERS

  • Abbott Laboratories
  • B. Braun Melsungen AG
  • Danone Nutricia
  • Baxter International Inc.
  • Fresenius SE & Co. KGaA
  • Perrigo Company Plc
  • Pfizer Inc
  • Nestle S.A
  • Lonza Ltd
  • Hero Nutritionals Inc
  • The other players in the value chain (profiles not included in the report)
  • Quantel laser
  • Nidek CO., LTD.
  • Topcon Corporation
  • DEKA M.E.L.A. S.r.l.
  • SharpLight Technologies
  • Sciton, Inc.
  • Alma Lasers

TABLE OF CONTENTS

CHAPTER 1:INTRODUCTION

  • 1.1.Report description
  • 1.2.Key benefits for stakeholders
  • 1.3.Key market segments
  • 1.4.Research methodology
    • 1.4.1.Secondary research
    • 1.4.2.Primary research
    • 1.4.3.Analyst tools & models

CHAPTER 2:EXECUTIVE SUMMARY

  • 2.1.Key findings of the study
  • 2.2.CXO perspective

CHAPTER 3:MARKET OVERVIEW

  • 3.1.Market definition and scope
  • 3.2.Key Findings
    • 3.2.1.Top Investment Pockets
  • 3.3.Market dynamics
    • 3.3.1.Drivers
      • 3.3.1.1.Rise in incidence of chronic diseases and lifestyle associated disease
      • 3.3.1.2.Increasing incidence of cancer and central nervous system (CNS) diseases
      • 3.3.1.3.Surge in geriatric population across the globe
    • 3.3.2.Restraint
      • 3.3.2.1.Lack of awareness for clinical nutrition
      • 3.3.2.2.Stringent regulations and poor reimbursement policies
    • 3.3.3.Opportunities
      • 3.3.3.1.Various growth opportunities in emerging economies
  • 3.4.Impact of COVID-19 on Clinical Nutrition Market

CHAPTER 4:CLINICAL NUTRITION MARKET, BY ROUTE OF ADMINISTRATION

  • 4.1.Overview
    • 4.1.1.Market size and forecast
  • 4.2.Oral
    • 4.2.1.Key market trends and opportunities
    • 4.2.2.Market size and forecast
    • 4.2.3.Market analysis, by country
  • 4.3.Enteral
    • 4.3.1.Key trends and opportunities
    • 4.3.2.Market size and forecast
    • 4.3.3.Market analysis, by country
  • 4.4.Parenteral
    • 4.4.1.Key market trends and opportunities
    • 4.4.2.Market size and forecast
    • 4.4.3.Market analysis, by country

CHAPTER 5:CLINICAL NUTRITION MARKET, BY APPLICATION

  • 5.1.Overview
    • 5.1.1.Market size and forecast
  • 5.2.Cancer
    • 5.2.1.Market size and forecast
    • 5.2.2.Market analysis, by country
  • 5.3.Neurological Diseases
    • 5.3.1.Market size and forecast
    • 5.3.2.Market analysis, by country
  • 5.4.Gastrointestinal Disorders
    • 5.4.1.Market size and forecast
    • 5.4.2.Market analysis, by country
  • 5.5.Metabolic Disorders
    • 5.5.1.Market size and forecast
    • 5.5.2.Market analysis, by country
  • 5.6.Others
    • 5.6.1.Market size and forecast
    • 5.6.2.Market analysis, by country

CHAPTER 6:CLINICAL NUTRITION MARKET, BY END USER

  • 6.1.Overview
    • 6.1.1.Market size and forecast
  • 6.2.Pediatric
    • 6.2.1.Market size and forecast
    • 6.2.2.Market analysis, by country
  • 6.3.Adults
    • 6.3.1.Market size and forecast
    • 6.3.2.Market analysis, by country
  • 6.4.Geriatric
    • 6.4.1.Market size and forecast
    • 6.4.2.Market analysis, by country

CHAPTER 7:CLINICAL NUTRITION MARKET, BY REGION

  • 7.1.Overview
    • 7.1.1.Market size and forecast
  • 7.2.North America
    • 7.2.1.Key trends and opportunities
    • 7.2.2.Market size and forecast, by country
    • 7.2.3.Market size and forecast, by route of administration
    • 7.2.4.Market size and forecast, by application
    • 7.2.5.Market size and forecast, by end user
    • 7.2.6.U.S.
      • 7.2.6.1.U.S. market size and forecast, by route of administration
      • 7.2.6.2.U.S. market size and forecast, by application
      • 7.2.6.3.U.S. market size and forecast, by end user
    • 7.2.7.Canada
      • 7.2.7.1.Canada market size and forecast, by route of administration
      • 7.2.7.2.Canada market size and forecast, by application
      • 7.2.7.3.Canada market size and forecast, by end user
    • 7.2.8.Mexico
      • 7.2.8.1.Mexico market size and forecast, by route of administration
      • 7.2.8.2.Mexico market size and forecast, by application
      • 7.2.8.3.Mexico market size and forecast, by end user
  • 7.3.Europe
    • 7.3.1.Key trends and opportunities
    • 7.3.2.Europe market size and forecast, by country
    • 7.3.3.Europe market size and forecast, by route of administration
    • 7.3.4.Europe market size and forecast, by application
    • 7.3.5.Europe market size and forecast, by end user
    • 7.3.6.Germany
      • 7.3.6.1.Germany market size and forecast, by route of administration
      • 7.3.6.2.Germany market size and forecast, by application
      • 7.3.6.3.Germany market size and forecast, by end user
    • 7.3.7.UK
      • 7.3.7.1.UK market size and forecast, by route of administration
      • 7.3.7.2.UK market size and forecast, by application
      • 7.3.7.3.UK market size and forecast, by end user
    • 7.3.8.Spain
      • 7.3.8.1.Spain market size and forecast, by route of administration
      • 7.3.8.2.Spain market size and forecast, by application
      • 7.3.8.3.Spain market size and forecast, by end user
    • 7.3.9.France
      • 7.3.9.1.France market size and forecast, by route of administration
      • 7.3.9.2.France market size and forecast, by application
      • 7.3.9.3.France market size and forecast, by end user
    • 7.3.10.Italy
      • 7.3.10.1.Italy market size and forecast, by route of administration
      • 7.3.10.2.Italy market size and forecast, by application
      • 7.3.10.3.Italy market size and forecast, by end user
    • 7.3.11.Rest of Europe
      • 7.3.11.1.Rest of Europe market size and forecast, by route of administration
      • 7.3.11.2.Rest of Europe market size and forecast, by application
      • 7.3.11.3.Rest of Europe market size and forecast, by end user
  • 7.4.Asia-Pacific
    • 7.4.1.Key trends and opportunities
    • 7.4.2.Asia-Pacific market size and forecast, by country
    • 7.4.3.Asia-Pacific market size and forecast, by route of administration
    • 7.4.4.Asia-Pacific market size and forecast, by application
    • 7.4.5.Asia-Pacific market size and forecast, by end user
    • 7.4.6.Japan
      • 7.4.6.1.Japan market size and forecast, by route of administration
      • 7.4.6.2.Japan market size and forecast, by application
      • 7.4.6.3.Japan market size and forecast, by end user
    • 7.4.7.China
      • 7.4.7.1.China market size and forecast, by route of administration
      • 7.4.7.2.China market size and forecast, by application
      • 7.4.7.3.China market size and forecast, by end user
    • 7.4.8.India
      • 7.4.8.1.India market size and forecast, by route of administration
      • 7.4.8.2.India market size and forecast, by application
      • 7.4.8.3.India market size and forecast, by end user
    • 7.4.9.Australia
      • 7.4.9.1.Australia market size and forecast, by route of administration
      • 7.4.9.2.Australia market size and forecast, by application
      • 7.4.9.3.Australia market size and forecast, by end user
    • 7.4.10.South Korea
      • 7.4.10.1.South Korea market size and forecast, by route of administration
      • 7.4.10.2.South Korea market size and forecast, by application
      • 7.4.10.3.South Korea market size and forecast, by end user
    • 7.4.11.Rest of Asia-Pacific
      • 7.4.11.1.Rest of Asia-Pacific market size and forecast, by route of administration
      • 7.4.11.2.Rest of Asia-Pacific market size and forecast, by application
      • 7.4.11.3.Rest of Asia-Pacific market size and forecast, by end user
  • 7.5.LAMEA
    • 7.5.1.Key market trends and opportunities
    • 7.5.2.LAMEA market size and forecast, by country
    • 7.5.3.LAMEA market size and forecast, by route of administration
    • 7.5.4.LAMEA market size and forecast, by application
    • 7.5.5.LAMEA market size and forecast, by end user
    • 7.5.6.Brazil
      • 7.5.6.1.Brazil market size and forecast, by route of administration
      • 7.5.6.2.Brazil market size and forecast, by application
      • 7.5.6.3.Brazil market size and forecast, by end user
    • 7.5.7.South Africa
      • 7.5.7.1.South Africa market size and forecast, by route of administration
      • 7.5.7.2.South Africa market size and forecast, by application
      • 7.5.7.3.South Africa market size and forecast, by end user
    • 7.5.8.Saudi Arabia
      • 7.5.8.1.Saudi Arabia market size and forecast, by route of administration
      • 7.5.8.2.Saudi Arabia market size and forecast, by application
      • 7.5.8.3.Saudi Arabia market size and forecast, by end user
    • 7.5.9.Rest of LAMEA
      • 7.5.9.1.Rest of LAMEA market size and forecast, by route of administration
      • 7.5.9.2.Rest of LAMEA market size and forecast, by application
      • 7.5.9.3.Rest of LAMEA market size and forecast, by end user

CHAPTER 8:COMPANY PROFILES

  • 8.1.ABBOTT LABORATORIES
    • 8.1.1.Company overview
    • 8.1.2.Company snapshot
    • 8.1.3.Operating business segments
    • 8.1.4.Product portfolio
    • 8.1.5.Business performance
    • 8.1.6.Key strategic moves and developments
  • 8.2.B. BRAUN MELSUNGEN AG
    • 8.2.1.Company overview
    • 8.2.2.Company snapshot
    • 8.2.3.Operating business segments
    • 8.2.4.Product Portfolio
    • 8.2.5.Business performance
    • 8.2.6.Key strategic moves and developments
  • 8.3.BAXTER INTERNATIONAL INC.
    • 8.3.1.Company overview
    • 8.3.2.Company snapshot
    • 8.3.3.Operating business segments
    • 8.3.4.Product Portfolio
    • 8.3.5.Business performance
    • 8.3.6.Key strategic moves and developments
  • 8.4.DANONE NUTRICIA
    • 8.4.1.Company overview
    • 8.4.2.Company snapshot
    • 8.4.3.Operating business segments
    • 8.4.4.Product portfolio
  • 8.5.FRESENIUS SE & CO. KGAA
    • 8.5.1.Company overview
    • 8.5.2.Company snapshot
    • 8.5.3.Operating business segments
    • 8.5.4.Product portfolio
    • 8.5.5.Business performance
  • 8.6.HERO NUTRITIONALS INC.
    • 8.6.1.Company overview
    • 8.6.2.Company snapshot
    • 8.6.3.Operating business segments
    • 8.6.4.Product portfolio
  • 8.7.LONZA LTD.
    • 8.7.1.Company overview
    • 8.7.2.Company snapshot
    • 8.7.3.Operating business segments
    • 8.7.4.Product portfolio
    • 8.7.5.Business performance
    • 8.7.6.Key strategic moves and developments
  • 8.8.NESTLE S.A.
    • 8.8.1.Company overview
    • 8.8.2.Company snapshot
    • 8.8.3.Operating business segments
    • 8.8.4.Product portfolio
    • 8.8.5.Business performance
  • 8.9.PERRIGO COMPANY PLC
    • 8.9.1.Company overview
    • 8.9.2.Company snapshot
    • 8.9.3.Operating business segments
    • 8.9.4.Product portfolio
    • 8.9.5.Business performance
  • 8.10.PFIZER INC.
    • 8.10.1.Company overview
    • 8.10.2.Company snapshot
    • 8.10.3.Operating business segments
    • 8.10.4.Product portfolio
    • 8.10.5.Business performance

LIST OF TABLES

  • TABLE 01.CLINICAL NUTRITION MARKET, BY ROUTE OF ADMINISTRATION, 2020-2028 ($MILLION)
  • TABLE 02.ORAL CLINICAL NUTRITION MARKET, BY REGION, 2020-2028 ($MILLION)
  • TABLE 03.ENTERAL CLINICAL NUTRITION MARKET, BY REGION, 2020-2028 ($MILLION)
  • TABLE 04.PERENTERAL CLINICAL NUTRITION MARKET, BY REGION, 2020-2028 ($MILLION)
  • TABLE 05.CLINICAL NUTRITION MARKET, BY APPLICATION, 2020-2028 ($MILLION)
  • TABLE 06.CANCER CLINICAL NUTRITION MARKET, BY REGION, 2020-2028 ($MILLION)
  • TABLE 07.NEUROLOGICAL DISEASES CLINICAL NUTRITION MARKET, BY REGION, 2020-2028 ($MILLION)
  • TABLE 08.GASTROINTESTINAL DISEASES CLINICAL NUTRITION MARKET, BY REGION, 2020-2028 ($MILLION)
  • TABLE 09.METABOLIC DISORDERS CLINICAL NUTRITION MARKET, BY REGION, 2020-2028 ($MILLION)
  • TABLE 10.OTHERS CLINICAL NUTRITION MARKET, BY REGION, 2020-2028 ($MILLION)
  • TABLE 11.CLINICAL NUTRITION MARKET, BY END USER, 2020-2028 ($MILLION)
  • TABLE 12.PEDIATRIC CLINICAL NUTRITION MARKET, BY REGION, 2020-2028 ($MILLION)
  • TABLE 13.ADULT CLINICAL NUTRITION MARKET, BY REGION, 2020-2028 ($MILLION)
  • TABLE 14.GERIATRIC CLINICAL NUTRITION MARKET, BY REGION, 2020-2028 ($MILLION)
  • TABLE 15.CLINICAL NUTRITION MARKET, BY REGION, 2020-2028 ($MILLION)
  • TABLE 16.NORTH AMERICA CLINICAL NUTRITION MARKET, BY COUNTRY, 2020-2028 ($MILLION)
  • TABLE 17.NORTH AMERICA CLINICAL NUTRITION MARKET, BY ROUTE OF ADMINISTRATION, 2020-2028 ($MILLION)
  • TABLE 18.NORTH AMERICA CLINICAL NUTRITION MARKET, BY APPLICATION, 2020-2028 ($MILLION)
  • TABLE 19.NORTH AMERICA CLINICAL NUTRITION MARKET, BY END USER, 2020-2028 ($MILLION)
  • TABLE 20.U.S. CLINICAL NUTRITION MARKET, BY ROUTE OF ADMINISTRATION, 2020-2028 ($MILLION)
  • TABLE 21.U.S. CLINICAL NUTRITION MARKET, BY APPLICATION, 2020-2028 ($MILLION)
  • TABLE 22.U.S. CLINICAL NUTRITION MARKET, BY END USER, 2020-2028 ($MILLION)
  • TABLE 23.CANADA CLINICAL NUTRITION MARKET, BY ROUTE OF ADMINISTRATION, 2020-2028 ($MILLION)
  • TABLE 24.CANADA CLINICAL NUTRITION MARKET, BY APPLICATION, 2020-2028 ($MILLION)
  • TABLE 25.CANADA CLINICAL NUTRITION MARKET, BY END USER, 2020-2028 ($MILLION)
  • TABLE 26.MEXICO CLINICAL NUTRITION MARKET, BY ROUTE OF ADMINISTRATION, 2020-2028 ($MILLION)
  • TABLE 27.MEXICO CLINICAL NUTRITION MARKET, BY APPLICATION, 2020-2028 ($MILLION)
  • TABLE 28.MEXICO CLINICAL NUTRITION MARKET, BY END USER, 2020-2028 ($MILLION)
  • TABLE 29.EUROPE CLINICAL NUTRITION MARKET, BY COUNTRY, 2020-2028 ($MILLION)
  • TABLE 30.EUROPE CLINICAL NUTRITION MARKET, BY ROUTE OF ADMINISTRATION, 2020-2028 ($MILLION)
  • TABLE 31.EUROPE CLINICAL NUTRITION MARKET, BY APPLICATION, 2020-2028 ($MILLION)
  • TABLE 32.EUROPE CLINICAL NUTRITION MARKET, BY END USER, 2020-2028 ($MILLION)
  • TABLE 33.GERMANY CLINICAL NUTRITION MARKET, BY ROUTE OF ADMINISTRATION, 2020-2028 ($MILLION)
  • TABLE 34.GERMANY CLINICAL NUTRITION MARKET, BY APPLICATION, 2020-2028 ($MILLION)
  • TABLE 35.GERMANY CLINICAL NUTRITION MARKET, BY END USER, 2020-2028 ($MILLION)
  • TABLE 36.UK CLINICAL NUTRITION MARKET, BY ROUTE OF ADMINISTRATION, 2020-2028 ($MILLION)
  • TABLE 37.UK CLINICAL NUTRITION MARKET, BY APPLICATION, 2020-2028 ($MILLION)
  • TABLE 38.UK CLINICAL NUTRITION MARKET, BY END USER, 2020-2028 ($MILLION)
  • TABLE 39.SPAIN CLINICAL NUTRITION MARKET, BY ROUTE OF ADMINISTRATION, 2020-2028 ($MILLION)
  • TABLE 40.SPAIN CLINICAL NUTRITION MARKET, BY APPLICATION, 2020-2028 ($MILLION)
  • TABLE 41.SPAIN CLINICAL NUTRITION MARKET, BY END USER, 2020-2028 ($MILLION)
  • TABLE 42.FRANCE CLINICAL NUTRITION MARKET, BY ROUTE OF ADMINISTRATION, 2020-2028 ($MILLION)
  • TABLE 43.FRANCE CLINICAL NUTRITION MARKET, BY APPLICATION, 2020-2028 ($MILLION)
  • TABLE 44.FRANCE CLINICAL NUTRITION MARKET, BY END USER, 2020-2028 ($MILLION)
  • TABLE 45.ITALY CLINICAL NUTRITION MARKET, BY ROUTE OF ADMINISTRATION, 2020-2028 ($MILLION)
  • TABLE 46.ITALY CLINICAL NUTRITION MARKET, BY APPLICATION, 2020-2028 ($MILLION)
  • TABLE 47.ITALY CLINICAL NUTRITION MARKET, BY END USER, 2020-2028 ($MILLION)
  • TABLE 48.REST OF EUROPE CLINICAL NUTRITION MARKET, BY ROUTE OF ADMINISTRATION, 2020-2028 ($MILLION)
  • TABLE 49.REST OF EUROPE CLINICAL NUTRITION MARKET, BY APPLICATION, 2020-2028 ($MILLION)
  • TABLE 50.REST OF EUROPE CLINICAL NUTRITION MARKET, BY END USER, 2020-2028 ($MILLION)
  • TABLE 51.ASIA-PACIFIC CLINICAL NUTRITION MARKET, BY COUNTRY, 2020-2028 ($MILLION)
  • TABLE 52.ASIA-PACIFIC CLINICAL NUTRITION MARKET, BY ROUTE OF ADMINISTRATION, 2020-2028 ($MILLION)
  • TABLE 53.ASIA-PACIFIC CLINICAL NUTRITION MARKET, BY APPLICATION, 2020-2028 ($MILLION)
  • TABLE 54.ASIA-PACIFIC CLINICAL NUTRITION MARKET, BY END USER, 2020-2028 ($MILLION)
  • TABLE 55.JAPAN CLINICAL NUTRITION MARKET, BY ROUTE OF ADMINISTRATION, 2020-2028 ($MILLION)
  • TABLE 56.JAPAN CLINICAL NUTRITION MARKET, BY APPLICATION, 2020-2028 ($MILLION)
  • TABLE 57.JAPAN CLINICAL NUTRITION MARKET, BY END USER, 2020-2028 ($MILLION)
  • TABLE 58.CHINA CLINICAL NUTRITION MARKET, BY ROUTE OF ADMINISTRATION, 2020-2028 ($MILLION)
  • TABLE 59.CHINA CLINICAL NUTRITION MARKET, BY APPLICATION, 2020-2028 ($MILLION)
  • TABLE 60.CHINA CLINICAL NUTRITION MARKET, BY END USER, 2020-2028 ($MILLION)
  • TABLE 61.INDIA CLINICAL NUTRITION MARKET, BY ROUTE OF ADMINISTRATION, 2020-2028 ($MILLION)
  • TABLE 62.INDIA CLINICAL NUTRITION MARKET, BY APPLICATION, 2020-2028 ($MILLION)
  • TABLE 63.INDIA CLINICAL NUTRITION MARKET, BY END USER, 2020-2028 ($MILLION)
  • TABLE 64.AUSTRALIA CLINICAL NUTRITION MARKET, BY ROUTE OF ADMINISTRATION, 2020-2028 ($MILLION)
  • TABLE 65.AUSTRALIA CLINICAL NUTRITION MARKET, BY APPLICATION, 2020-2028 ($MILLION)
  • TABLE 66.AUSTRALIA CLINICAL NUTRITION MARKET, BY END USER, 2020-2028 ($MILLION)
  • TABLE 67.SOUTH KOREA CLINICAL NUTRITION MARKET, BY ROUTE OF ADMINISTRATION, 2020-2028 ($MILLION)
  • TABLE 68.SOUTH KOREA CLINICAL NUTRITION MARKET, BY APPLICATION, 2020-2028 ($MILLION)
  • TABLE 69.SOUTH KOREA CLINICAL NUTRITION MARKET, BY END USER, 2020-2028 ($MILLION)
  • TABLE 70.REST OF ASIA-PACIFIC CLINICAL NUTRITION MARKET, BY ROUTE OF ADMINISTRATION, 2020-2028 ($MILLION)
  • TABLE 71.REST OF ASIA-PACIFIC CLINICAL NUTRITION MARKET, BY APPLICATION, 2020-2028 ($MILLION)
  • TABLE 72.REST OF ASIA-PACIFIC CLINICAL NUTRITION MARKET, BY END USER, 2020-2028 ($MILLION)
  • TABLE 73.LAMEA CLINICAL NUTRITION MARKET, BY COUNTRY, 2020-2028 ($MILLION)
  • TABLE 74.LAMEA CLINICAL NUTRITION MARKET, BY ROUTE OF ADMINISTRATION, 2020-2028 ($MILLION)
  • TABLE 75.LAMEA CLINICAL NUTRITION MARKET, BY APPLICATION, 2020-2028 ($MILLION)
  • TABLE 76.LAMEA CLINICAL NUTRITION MARKET, BY END USER, 2020-2028 ($MILLION)
  • TABLE 77.BRAZIL CLINICAL NUTRITION MARKET, BY ROUTE OF ADMINISTRATION, 2020-2028 ($MILLION)
  • TABLE 78.BRAZIL CLINICAL NUTRITION MARKET, BY APPLICATION, 2020-2028 ($MILLION)
  • TABLE 79.BRAZIL CLINICAL NUTRITION MARKET, BY END USER, 2020-2028 ($MILLION)
  • TABLE 80.SOUTH AFRICA CLINICAL NUTRITION MARKET, BY ROUTE OF ADMINISTRATION, 2020-2028 ($MILLION)
  • TABLE 81.SOUTH AFRICA CLINICAL NUTRITION MARKET, BY APPLICATION, 2020-2028 ($MILLION)
  • TABLE 82.SOUTH AFRICA CLINICAL NUTRITION MARKET, BY END USER, 2020-2028 ($MILLION)
  • TABLE 83.SAUDI ARABIA CLINICAL NUTRITION MARKET, BY ROUTE OF ADMINISTRATION, 2020-2028 ($MILLION)
  • TABLE 84.SAUDI ARABIA CLINICAL NUTRITION MARKET, BY APPLICATION, 2020-2028 ($MILLION)
  • TABLE 85.SAUDI ARABIA CLINICAL NUTRITION MARKET, BY END USER, 2020-2028 ($MILLION)
  • TABLE 86.REST OF LAMEA CLINICAL NUTRITION MARKET, BY ROUTE OF ADMINISTRATION, 2020-2028 ($MILLION)
  • TABLE 87.REST OF LAMEA CLINICAL NUTRITION MARKET, BY APPLICATION, 2020-2028 ($MILLION)
  • TABLE 88.REST OF LAMEA CLINICAL NUTRITION MARKET, BY END USER, 2020-2028 ($MILLION)
  • TABLE 89.ABBOTT: COMPANY SNAPSHOT
  • TABLE 90.ABBOTT: OPERATING SEGMENTS
  • TABLE 91.ABBOTT: PRODUCT PORTFOLIO
  • TABLE 92.B. BRAUN: COMPANY SNAPSHOT
  • TABLE 93.B. BRAUN: OPERATING SEGMENTS
  • TABLE 94.B. BRAUN: PRODUCT PORTFOLIO
  • TABLE 95.BAXTER: COMPANY SNAPSHOT
  • TABLE 96.BAXTER: BUSINESS SEGMENT
  • TABLE 97.NUTRICIA: COMPANY SNAPSHOT
  • TABLE 98.NUTRICIA: OPERATING SEGMENTS
  • TABLE 99.NUTRICIA: PRODUCT PORTFOLIO
  • TABLE 100.FRESENIUS: COMPANY SNAPSHOT
  • TABLE 101.FRESENIUS: OPERATING SEGMENTS
  • TABLE 102.FRESENIUS: PRODUCT PORTFOLIO
  • TABLE 103.HERO: COMPANY SNAPSHOT
  • TABLE 104.HERO: OPERATING SEGMENTS
  • TABLE 105.HERO: PRODUCT PORTFOLIO
  • TABLE 106.LONZA: COMPANY SNAPSHOT
  • TABLE 107.LONZA: OPERATING SEGMENTS
  • TABLE 108.LONZA: PRODUCT PORTFOLIO
  • TABLE 109.NESTLE: COMPANY SNAPSHOT
  • TABLE 110.NESTLE: OPERATING SEGMENTS
  • TABLE 111.NESTLE: PRODUCT PORTFOLIO
  • TABLE 112.PERRIGO: COMPANY SNAPSHOT
  • TABLE 113.PERRIGO: OPERATING SEGMENTS
  • TABLE 114.PERRIGO: PRODUCT PORTFOLIO
  • TABLE 115.PFIZER: COMPANY SNAPSHOT
  • TABLE 116.PFIZER: OPERATING SEGMENTS
  • TABLE 117.PFIZER: PRODUCT PORTFOLIO

LIST OF FIGURES

  • FIGURE 01.CLINICAL NUTRITION MARKET SEGMENTATION
  • FIGURE 02.TOP INVESTMENT POCKETS
  • FIGURE 03.CLINICAL NUTRITION MARKET: DRIVERS, RESTRAINTS, AND OPPORTUNITIES
  • FIGURE 04.COMPARATIVE SHARE ANALYSIS OF ORAL CLINICAL NUTRITION MARKET, BY COUNTRY, 2020 & 2028 (%)
  • FIGURE 05.COMPARATIVE SHARE ANALYSIS OF ENTERAL CLINICAL NUTRITION MARKET, BY COUNTRY, 2020 & 2028 (%)
  • FIGURE 06.COMPARATIVE SHARE ANALYSIS OF PERENTERAL CLINICAL NUTRITION MARKET, BY COUNTRY, 2020 & 2028 (%)
  • FIGURE 07.COMPARATIVE SHARE ANALYSIS OF CANCER CLINICAL NUTRITION MARKET, BY COUNTRY, 2020 & 2028 (%)
  • FIGURE 08.COMPARATIVE SHARE ANALYSIS OF NEUROLOGICAL DISEASES CLINICAL NUTRITION MARKET BY COUNTRY, 2020 & 2028 (%)
  • FIGURE 09.COMPARATIVE SHARE ANALYSIS OF GASTROINTESTINAL DISEASES CLINICAL NUTRITION MARKET BY COUNTRY, 2020 & 2028 (%)
  • FIGURE 10.COMPARATIVE SHARE ANALYSIS OF METABOLIC DISORDERS CLINICAL NUTRITION MARKET BY COUNTRY, 2020 & 2028 (%)
  • FIGURE 11.COMPARATIVE SHARE ANALYSIS OF OTHERS CLINICAL NUTRITION MARKET BY COUNTRY, 2020 & 2028 (%)
  • FIGURE 12.COMPARATIVE SHARE ANALYSIS OF PEDIATRIC CLINICAL NUTRITION MARKET, BY COUNTRY, 2020 & 2028 (%)
  • FIGURE 13.COMPARATIVE SHARE ANALYSIS OF ADULT CLINICAL NUTRITION MARKET BY COUNTRY, 2020 & 2028 (%)
  • FIGURE 14.COMPARATIVE SHARE ANALYSIS OF GERIATRIC CLINICAL NUTRITION MARKET BY COUNTRY, 2020 & 2028 (%)
  • FIGURE 15.ABBOTT: NET SALES, 2019-2020 ($MILLION)
  • FIGURE 16.ABBOTT: REVENUE SHARE BY SEGMENT, 2020 (%)
  • FIGURE 17.ABBOTT: REVENUE SHARE BY REGION, 2020 (%)
  • FIGURE 18.NET SALES, 2019-2020 ($MILLION)
  • FIGURE 19.B. BRAUN: NET SALES BY DIVISION, 2020 (%)
  • FIGURE 20.B. BRAUN: NET SALES BY REGION, 2020 (%)
  • FIGURE 21.NET SALES, 2019-2020 ($MILLION)
  • FIGURE 22.BAXTER: REVENUE SHARE BY BUSINESS UNIT, 2020 (%)
  • FIGURE 23.BAXTER: REVENUE SHARE BY REGION, 2020 (%)
  • FIGURE 24.FRESENIUS: NET SALES, 2019-2020 ($MILLION)
  • FIGURE 25.FRESENIUS: REVENUE SHARE BY SEGMENT, 2020 (%)
  • FIGURE 26.FRESENIUS: REVENUE SHARE BY REGION, 2020(%)
  • FIGURE 27.NET SALES, 2019-2020 ($MILLION)
  • FIGURE 28.LONZA: REVENUE SHARE BY SEGMENT, 2020 (%)
  • FIGURE 29.LONZA: REVENUE SHARE BY REGION, 2020 (%)
  • FIGURE 30.NET SALES, 2019-2020 ($MILLION)
  • FIGURE 31.NESTLE: REVENUE SHARE BY SEGMENT, 2020 (%)
  • FIGURE 32.NESTLE: REVENUE SHARE BY REGION, 2020 (%)
  • FIGURE 33.PERRIGO: NET SALES, 2019-2020 ($MILLION)
  • FIGURE 34.PERRIGO: REVENUE SHARE BY SEGMENT, 2020 (%)
  • FIGURE 35.PERRIGO: REVENUE SHARE BY REGION, 2020 (%)
  • FIGURE 36.PFIZER NET SALES, 2019-2020 ($MILLION)
  • FIGURE 37.PFIZER: REVENUE SHARE BY SEGMENT, 2020 (%)
  • FIGURE 38.PFIZER: REVENUE SHARE BY GEOGRAPHY, 2020 (%)